GeneTether Therapeutics (XCNQ:GTTX) Ending Cash Position : C$1.70 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Ending Cash Position?

GeneTether Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was C$1.70 Mil.

GeneTether Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 (C$1.84 Mil) to Dec. 2023 (C$1.83 Mil) and declined from Dec. 2023 (C$1.83 Mil) to Mar. 2024 (C$1.70 Mil).

GeneTether Therapeutics's annual Ending Cash Position increased from Dec. 2021 (C$0.23 Mil) to Dec. 2022 (C$2.44 Mil) but then declined from Dec. 2022 (C$2.44 Mil) to Dec. 2023 (C$1.83 Mil).

GeneTether Therapeutics Ending Cash Position Historical Data

The historical data trend for GeneTether Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Ending Cash Position Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

0.06

0.23

2.44

1.83

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial									2.30	1.91	1.84	1.83	1.70

GeneTether Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GeneTether Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.41	+	-0.58
	=	1.83

GeneTether Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.846	+	-0.15
	=	1.70

GeneTether Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines